News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2024

28 October, 2024 Egetis Therapeutics publishes prospectus for admission to trading of shares on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
25 October, 2024 Bulletin from Egetis Therapeutics’ Extraordinary General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
4 October, 2024 Change in the Board of Directors of Egetis Therapeutics News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
30 September, 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
30 September, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
30 September, 2024 Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
22 August, 2024 Interim report Q2 2024 News English Regulatory MAR VPML Report Interim Q2 IR Optional
19 June, 2024 Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
6 May, 2024 Bulletin from Egetis Therapeutics’ Annual General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
3 May, 2024 Interim report Q1 2024 News English Regulatory MAR Report Interim Q1 IR Optional
24 April, 2024 The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ) News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
15 April, 2024 Egetis Therapeutics’ 2023 Annual Report published News English Regulatory VPML Report Annual IR Optional
29 March, 2024 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
22 February, 2024 Year-End report January-December 2023 News English Regulatory MAR Report Interim Yearend IR Optional

2023

10 November, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan News Corporate Action Other English Regulatory MAR IR Optional
8 November, 2023 Interim report Q3 2023 News English Regulatory MAR Report Interim Q3 IR Optional
1 November, 2023 Egetis’ Nomination Committee for the 2024 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
31 October, 2023 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
11 October, 2023 Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory LHFI IR Optional
22 August, 2023 Interim report Q2 2023 News English Regulatory MAR VPML Report Interim Q2 IR Optional
28 June, 2023 Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
31 May, 2023 Board director in Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
23 May, 2023 Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

Calendar and upcoming reports

November 8, 2024
Interim Report Q3 2024 (7:00am CET)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]